Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors

Authors
Category Primary study
JournalMolecular Cancer Therapeutics
Year 2015
This article has no abstract
Epistemonikos ID: 571ed5a1e8d867ba6bb7e5bfb362c4bc527a0349
First added on: Feb 07, 2025